MedPath

Evaluation of Glycemic Control by Flash Monitoring of Glucose (MFG) in Malnourished Patients With Type 2 Diabetes

Not Applicable
Conditions
Diabetes Type 2
Malnutrition
Interventions
Other: Fortimel energy
Other: Nutrision Advanced Diason Energy HP
Registration Number
NCT05443204
Lead Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Brief Summary

Evaluation of Glycemic Control by Flash Monitoring of Glucose (MFG) in Malnourished Patients With Type 2 Diabetes (MFG SNO)

Detailed Description

In people with malnutrition and diabetes who require oral supplementation, there is no evidence clear when choosing a specific supplement for diabetes or a standard supplement. To date, there are no studies evaluating flash glucose monitoring in people with DM2 with supplements, nor studies comparing formulas specific for diabetes with standard formulas. Patients with type 2 diabetes, malnutrition and requiring oral nutritional supplements for 3 months will be included in the study.

A standard supplement (minimum 2 per day) will be prescribed for 2 weeks, an installation of the MFG system indicating that the scans are performed at start up, at the time and two hours after taking the oral supplement at home, as it doesn't happen anymore 8 hours without scanning to avoid losing information. After 14 days participants will go to consultation to download MFG data, assess acute response after taking of the supplement in the presence of health personnel (every 15 minutes for 4 hours). Investigators will change the sensor and nutritional supplement to a specific diabetes formula, after 14 days participants will come for MFG data download and to assess acute response after taking the supplement in the presence of healthcare personnel.

The results of the study will allow us to carry out a more appropriate treatment in this profile of patients, which is increasingly prevalent in our consultations.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Patients with DM2 under follow-up by the Clinical Nutrition and Dietetics Unit (UNCYD) who present malnutrition or are at risk of malnutrition and require oral nutritional supplements, for a minimum estimated period of 3 months.
Exclusion Criteria
  • Patients with DM1, steroid diabetes, pancreatic diabetes, DM2 treated with rapid insulin, glomerular filtration rate less than 30 mL/min/1.73m2, intolerance to the product, gastrectomy or gastroparesis.
  • Patients who do not sign the consent informed.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard Formula (Fortimel)Fortimel energyFats 35% total caloric volume (VCT) Carbohydrates: 49% del VCT Proteins: 16% del VCT Density: 1.5 kcal/ ml
Specific formula for diabetes (Nutrision Advanced)Nutrision Advanced Diason Energy HPFats: 46% del VCT (60% monounsaturated fatty acids) Carbohydrates: 31% del VCT Proteins: 21% del VFiber: 2% VCT (80% soluble y 20% insoluble) Density: 1.5kcal/ml
Primary Outcome Measures
NameTimeMethod
MFG discharge - mean interstitial glucoseDuring 14 days after taking the supplement

Interstitial glucose measured in mg/dl

MFG discharge - hyperglycaemiaDuring 14 days after taking the supplement

hyperglycaemia measured in mg/dl

MFG discharge - hypoglycaemiaDuring 14 days after taking the supplement

hypoglycaemia measured in mg/dl

MFG discharge - GMIDuring 14 days after taking the supplement

Measured in number of scans per day

MFG discharge - hypoglycaemic eventsDuring 14 days after taking the supplement

Measured in number and duration per day

Secondary Outcome Measures
NameTimeMethod
Postprandial glucose intersticial monitoringdiabetes specific supplementDuring the 4 hours after taking standard formula and the one specific for diabetes

Glucose intersticial measured in mg/dl

Trial Locations

Locations (1)

Hospital Regional Universitario de Málaga

🇪🇸

Málaga, Spain

© Copyright 2025. All Rights Reserved by MedPath